2026-01-02 - Analysis Report
Okay, here's a breakdown and analysis of Recursion Pharmaceuticals (RXRX) based on the provided data, following your requested format:

**0) Report in English, starting with simple numbers:**

**1) Return Rate Comparison:**

*   **Ticker:** RXRX
*   **Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence to discover and develop drugs.
*   **RXRX Cumulative Return:** -33.76%
*   **S&P 500 (VOO) Cumulative Return:** 43.29%
*   **Divergence:**
    *   Max: 84.1
    *   Min: -78.2
    *   Current: -77.0
    *   Relative Divergence: 0.7

**Analysis:** RXRX has significantly underperformed the S&P 500.  The current divergence is near its minimum, suggesting the underperformance is particularly pronounced.  The relative divergence of 0.7 indicates that the current level of divergence is near the lowest it has been within the defined range.

**Alpha, Beta Analysis Table:**

| Year       | CAGR  | MDD   | Alpha  | Beta | Cap(B) |
|------------|-------|-------|--------|------|--------|
| 2022-2024  | -43.0% | 82.1% | -73.0% | 2.3 | 3.5 |
| 2023-2025  | -51.0% | 88.8% | -119.0%| 2.6 | 2.1 |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Shows a substantial *loss* in value over both periods.
*   **MDD (Maximum Drawdown):**  Very high, indicating significant price volatility and risk. A drawdown of 88.8% means the stock lost 88.8% of its peak value at some point during 2023-2025.
*   **Alpha:** Highly negative, meaning RXRX has significantly underperformed relative to its benchmark (S&P 500).
*   **Beta:** Above 1, indicating RXRX is more volatile than the market.
*   **Cap(B):** Indicates market capitalization in billions. Decreasing from 3.5B to 2.1B from 2022-2024 to 2023-2025 respectively.

**2) Recent Stock Price Fluctuations:**

*   **Current Price:** 4.09
*   **Previous Close:** 4.11
*   **Change:** -0.49%
*   **5-day SMA:** 4.196
*   **20-day SMA:** 4.454
*   **60-day SMA:** 4.9225

**Analysis:** The stock price is currently below its 5-day, 20-day, and 60-day Simple Moving Averages (SMAs). This suggests a short-term downtrend.  The further the price is below the SMAs, the stronger the indication of a downtrend. The recent price change of -0.49 is minor so it doesn't look like a sharp rebound or decline.

**3) RSI, PPO, Delta_Previous_Relative_Divergence, Expected_Return Analysis:**

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment)
*   **RSI:** 33.00
*   **PPO:** -0.5268
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (228 shares - Very Safe - MRI:0.90) Monthly invest 1.7% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 0.7 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** 0.0

**Analysis:**

*   **MRI:** Suggests a medium level of investment risk, and according to the description, medium investment is recommended.
*   **RSI:** 33.00. RSI < 30 generally indicates that the stock is oversold and *could* be due for a bounce.
*   **PPO:** -0.5268. A negative PPO suggests the short-term moving average is below the long-term moving average, indicating a downtrend.
*   **Hybrid Signal:** The signal recommends buying, suggesting a potentially favorable outlook despite the current downtrend, and indicates 'Very Safe' but consider that a 'medium investment' is recommended, so it is not too risky to buy.
*   **Recent Relative Divergence Change:** Despite the overall underperformance, there has been a recent short-term increase in relative divergence. This suggests some positive momentum in the very recent past.
*   **Expected Return:** 0.0%. Suggests that over the long term (2+ years), no excess return is expected compared to the S&P 500 if invested from this point.

**4) Recent News & Significant Events:**

*   **Bearish Sentiment:**
    *   "RXRX Stock Plummet: Here’s What’s Happening"
    *   "Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy." (Suggests alternatives)
    *   "$RXRX stock fell 9% this week."
*   **Positive Catalysts:**
    *   "RXRX Stock Surges on JPMorgan Upgrade, Trial Data Gains"
    *   "Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition"

**Analysis:** The news sentiment is mixed. Negative headlines highlight the stock's recent struggles, while positive headlines point to potential catalysts like analyst upgrades, promising trial data, ARK Invest interest, and a future CEO transition. The "Forget Recursion..." articles are particularly concerning as they actively recommend alternative investments.

**4-2) Analyst Opinions:**

*   **Consensus:** No key information provided, unknown (~) mean rating.
*   **Opinions:** 7 analysts
*   **Target Price (avg/high/low):** 7.00 / 11.00 / 3.00

**Analysis:** There are 7 analyst opinions but the analyst consensus is unknown.  The average target price of $7.00 represents significant upside potential from the current price of $4.09. However, the wide range ($3.00 - $11.00) indicates a lack of strong conviction and differing views on the stock's future.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출  |
|------------|-------|-------|
| 2025-11-05 | -0.36 | 0.01 B$ |
| 2025-08-05 | -0.41 | 0.02 B$ |
| 2025-05-05 | -0.50 | 0.01 B$ |
| 2024-11-06 | -0.34 | 0.03 B$ |
| 2025-11-05 | -0.34 | 0.03 B$ |

**Analysis:**

*   **EPS (Earnings Per Share):** Consistently negative, indicating the company is not profitable. There's no clear improving trend.
*   **Revenue:** Low and fluctuating. Revenue appears to be decreasing over time.

**6) Financial Information (Revenue, Profitability, Capital):**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-09-30 | $0.00B   | -194.74%      |
| 2025-06-30 | $0.02B   | -5.54%        |
| 2025-03-31 | $0.01B   | -47.31%       |
| 2024-12-31 | $0.00B   | -183.62%      |
| 2024-09-30 | $0.03B   | 53.69%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-09-30 | $1.05B  | -15.50%  |
| 2025-06-30 | $0.92B  | -18.70%  |
| 2025-03-31 | $0.93B  | -21.68%  |
| 2024-12-31 | $1.03B  | -17.29%  |
| 2024-09-30 | $0.52B  | -18.27%  |

**Analysis:**

*   **Revenue:** Volatile and generally low.  Revenue has decreased to $0.00B for the most recent quarter.
*   **Profit Margin:** Consistently negative, reflecting the company's inability to generate profits. Extremely negative margins are concerning.
*   **Equity:**  Reasonable, reflecting a substantial amount of capital, but decreasing over time.
*   **ROE (Return on Equity):** Consistently negative, further reinforcing the company's lack of profitability.

**7) Comprehensive Analysis (Summary):**

Recursion Pharmaceuticals (RXRX) presents a high-risk, potentially high-reward investment opportunity.

*   **Negative Performance:** The stock has significantly underperformed the S&P 500, with a substantial negative cumulative return and high volatility (high MDD, Beta > 1). Its Alpha is also largely negative, indicating its inefficiency to generate revenue compared to benchmarks.
*   **Financial Concerns:** The company is currently unprofitable, with consistently negative EPS, profit margins, and ROE. Revenue is low and variable.
*   **Mixed Signals:**  While the recent news is mixed (some positive catalysts), the overall trend and financial data suggest caution. Analyst target prices indicate potential upside, but with a wide range of opinions.
*   **Technical Indicators:** The stock is in a short-term downtrend (price below SMAs), but the RSI suggests it may be oversold. The Hybrid Signal indicates a "buy".
*   **Investment Recommendation:** The Market Risk Indicator (MRI) suggests a medium investment. Given the high risk and negative financials, a **small**, speculative position might be considered if the investor is comfortable with significant volatility and potential losses.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.